Log in

Relevant bibliographies by topics / Cyclophosphamide / Books

To see the other types of publications on this topic, follow the link: Cyclophosphamide.

Books on the topic 'Cyclophosphamide'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Cyclophosphamide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Boche, Gernot. Cyclopropane derived reactive intermediates. Wiley, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

R, Nowrousian M., ed. Ifosfamide in cancer therapy: A comparison with cyclophosphamide. Universitätsverlag, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Asli-Yalfani, Esmael. Cellular and molecular studies of the immunopharmacology of cyclophosphamide. University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Azria, M. (Moïse). Calcitonins: Physiological and pharmacological aspects. Springer Verlag, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lewtas, Joellen. Final report on the evaluation of four toxic chemicals in an In Vivo/In Vitro toxicological screen--acrylamide, chlordecone, cyclophosphamide, and diethylstilbestrol. U.S. Environmental Protection Agency, Health Effects Research Laboratory, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lundbeck, Finn. The normal mouse urinary bladder reservoir function evaluated by repeated cystometries: Early and late changes after irradiation alone and irradiation combined with cis-diaminedichloroplatinum (II) or cyclophosphamide. Distributed by Scandinavian University Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gutenberg-Universität, Johannes, ed. Untersuchungen zur posttranslationalen Modifikation von Cytochrom P450 2B1 und deren Konsequenzen für die Aktivierung von Cyclophosphamid. [s.n.], 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Renk-Gees, Annemarie. Untersuchungen über den Gehalt an Adeninribonukleotiden und die Zellzahl von Mäuseembryonen in der Präimplantationsphase nach Behandlung mit Cyclophosphamid (Endoxan R). [s.n.], 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Karakas, Tunca. Therapie hochmaligner Non-Hodgkin-Lymphome: Eine Phase-II-Studie mit Vincristin, Adriamycin, Cyclophosphamid, Prednison und Etoposid (VACPE) sowie randomisiert rhGM-CSF. [s.n.], 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Blokdijk, G. J. Cyclophosphamide; The Ultimate Step-By-Step Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cyclophosphamide: Clinical Pharmacology, Uses and Potential Adverse Effects. Nova Science Publishers, Incorporated, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Publications, ICON Health. Cyclophosphamide - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Progress in Clinical Biochemistry and Medicine. Springer Verlag, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Chen, Chu-liang. Identification of an inguinal adipocyte-specific protein using monoclonal antibody selected by cyclophosphamide. 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Foster, Helen, and Paul A. Brogan, eds. British Society of Paediatric and Adolescent Rheumatology clinical guidelines and protocols. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199592630.003.0009.

Full text

Abstract:

BSPAR Standards of Care for children and young people with JIA 410BSPAR drug information leaflets for parents and families 412BSPAR guidelines for treatments used in paediatric rheumatology 415Non-steroidal anti-inflammatory drugs (NSAIDs) 416Disease-modifying anti-rheumatic drugs (DMARDs) 418Azathioprine 423Ciclosporin 425Intravenous cyclophosphamide ...

APA, Harvard, Vancouver, ISO, and other styles

16

Jayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.

Full text

Abstract:

The goals of treatment in anti-neutrophil cytoplasm antibody (ANCA) vasculitis are to stop vasculitic activity, to prevent vasculitis returning, and to address longer-term comorbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk. Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as methotrexate or azathioprine, to prevent relapse. Refractory disease resulting from a failure of induction or remission maintenance therapy requires alternative agents and rituximab has been par

APA, Harvard, Vancouver, ISO, and other styles

17

Harper, Lorraine, and David Jayne. The patient with vasculitis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0160.

Full text

Abstract:

The goals of treatment in renal vasculitis are to stop vasculitic activity and recover renal function. Subsequent strategies are required to prevent vasculitis returning and to address longer-term co-morbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk.Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as azathioprine, to prevent relapse. Plasma exchange improves renal recovery in severe presentations. Refractory disease resulting from a failure of induction or remission

APA, Harvard, Vancouver, ISO, and other styles

18

Hardy, Robert William. Analysis of cyclophosphamide and phosphoramide mustard, their pharmacokinetics and the relationship of serum drug concentrations to toxicity in patients undergoing cancer chemotherapy. 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Pagnoux, Christian, and Richard H. Swartz. Vasculitis of the Central Nervous System. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0099.

Full text

Abstract:

Central nervous system (CNS) vasculitis is an extremely challenging diagnostic and therapeutic disease. Multiple conditions, including reversible cerebral vasoconstrictive syndrome and intracranial atherosclerosis, can mimic it. Infections, systemic diseases, particularly systemic vasculitides, drug abuse, neoplasms, and some other disorders can cause secondary CNS vasculitis. Primary CNS vasculitis is extremely rare. A definite diagnosis requires a brain biopsy, which may show granulomatous inflammation, lymphocytic inflammation, and/or acute necrotizing vasculitis. The pathogeny remains unkn

APA, Harvard, Vancouver, ISO, and other styles

20

Wijdicks, Eelco F. M., and Sarah L. Clark. Immunosuppression and Immunotherapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190684747.003.0010.

Full text

Abstract:

Immune modulation in the neurosciences intensive care unit mostly involves high-dose corticosteroids, plasma exchange, and immunoglobulin. Corticosteroids are frequently used in patients with neurologic complications of cancer. Neurosurgeons typically use corticosteroids after performing a craniectomy to reduce cerebral edema. Corticosteroids are the established initial treatment modality of choice for patients with acute metastatic epidural spinal cord compression. Therapeutic apheresis or immunoglobulin is generally used as supportive therapy in patients with Guillain-Barré syndrome, myasthe

APA, Harvard, Vancouver, ISO, and other styles

21

Sandstrom, Marie. Pharmacokinetics & Pharmacodynamics of Anti-Cancer Regimens: Emphasis on Busulphan and the Combination Therapies Epirubicin-Docetaxal and Fluorouracil-Epirubicin-Cyclophosphamide ... from the Faculty of Pharmacy, 265). Uppsala Universitet, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Cui, Zhao, Neil Turner, and Ming-hui Zhao. Antiglomerular basement membrane disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0073_update_001.

Full text

Abstract:

Cyclophosphamide and plasma exchange are the standard of care in rapidly progressive glomerulonephritis or lung haemorrhage caused by antiglomerular basement membrane (anti-GBM) disease, and it is unusual to encounter patients at earlier stages. Steroids are universally used in addition. There is some evidence that plasma exchange may not be a critical part of treatment at an earlier stage. There is no more than anecdotal evidence for other therapies. Slower-onset therapies such as antibodies to B cells are rarely appropriate. If untreated, patients with severe anti-GBM disease will not recove

APA, Harvard, Vancouver, ISO, and other styles

23

Houssiau, Frédéric A. The patient with systemic lupus erythematosus. Edited by Giuseppe Remuzzi. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0163_update_001.

Full text

Abstract:

Major progress has been achieved in the field of lupus nephritis (LN) treatment over the last decade. Glucocorticoids and other immunosuppressants (including cyclophosphamide) are now used in a more patient-friendly way, minimizing their untoward effects. Mycophenolate mofetil is now an option, both for induction and maintenance immunosuppression. Ever increased standards for optimal global care have further contributed to lower end-stage renal disease rates.Better understanding of the mechanisms underlying lupus raises hopes for more targeted therapies with biologics. Thus, the anti-B-lymphoc

APA, Harvard, Vancouver, ISO, and other styles

24

Rahman, Anisur. Conventional treatments in systemic lupus erythematosus. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198739180.003.0006.

Full text

Abstract:

A new diagnosis of SLE can be frightening for patients, and the importance of education and reassurance must be remembered—clinical nurse specialists can play a key role in this. Equally, lifestyle advice regarding sun-protection and smoking cessation should not be neglected. Many patients have a mild disease characterized by ongoing symptoms such as rash, hair loss, and joint or chest pain. Symptomatic treatment, topical corticosteroids, antimalarials, and non-steroidal anti-inflammatory drugs are generally sufficient to manage these cases, but acute symptomatic flares may require short-term

APA, Harvard, Vancouver, ISO, and other styles

25

Wipprecht, Aline. Aktivierung Von Cyclophosphamid in Extrakten Aus Embryonalen Hühnerlebern. GRIN Verlag GmbH, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wells, Elizabeth M. Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0091.

Full text

Abstract:

Anti- N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe but treatable recently identified form of immune-mediated encephalitis associated with antibodies in serum and cerebrospinal fluid (CSF) against the GluN1 subunit of the NMDAR. Research has rapidly expanded the understanding of disease mechanisms and how the condition manifests in different populations (e.g., pediatrics vs. adult, cancer vs. noncancer, male vs. female). Immunocytochemical, physiological, and molecular studies of the effects of human CSF on the rodent and murine brain in vitro and in vivo indicate a noncytotox

APA, Harvard, Vancouver, ISO, and other styles

27

Lai, Kar Neng, and Sydney C. W. Tang. Immunoglobulin A nephropathy. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0068_update_001.

Full text

Abstract:

Immunoglobulin A nephropathy is characteristically slowly evolving, and studies from autopsies and kidney donors show that deposition of immunoglobulin A is quite common and not necessarily associated with overt disease. However, series of biopsy-diagnosed patients that extend to 20 or 30 years report rates of end-stage renal failure of up to 40–50%. A very approximate overall rate of end-stage renal disease of 1% per year has been suggested. Proteinuria, glomerular filtration rate (GFR), and possibly some features on renal biopsies enable risk stratification, but all patients need long-term m

APA, Harvard, Vancouver, ISO, and other styles

28

Bissell, Lesley-Anne, Dwomoa Adu, and Paul Emery. The patient with rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome, or polymyositis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0166.

Full text

Abstract:

Renal disease is a well-recognized cause of ill health and death in rheumatoid arthritis. Three broad categories of renal disease occur. The first—and by far the most common—arises from the nephrotoxicity of the drugs used in the treatment of arthritis, particularly with non-steroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as gold and D-penicillamine may lead to proteinuria and a glomerulonephritis in 10–30% of patients. Ciclosporin is associated with significant nephrotoxicity and hypertension. A second major but diminishing cause of renal disease in rheumatoid ar

APA, Harvard, Vancouver, ISO, and other styles

29

Cattran, Daniel C., and Heather N. Reich. Membranous glomerulonephritis. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0062_update_001.

Full text

Abstract:

A common rule of thumb in primary membranous glomerulonephritis (MGN) is that one-third of patients improve spontaneously, one-third progress, and one-third continue to have substantial proteinuria. The rate of spontaneous recovery may be near the truth, but MGN is usually an indolent condition and few studies have run long enough to give accurate outcomes for the remainder. However MGN is an important cause of end-stage renal failure. Treatment regimens that include cyclophosphamide or chlorambucil can improve the outcome of patients at greatest risk of deterioration, but their toxicity has l

APA, Harvard, Vancouver, ISO, and other styles

30

Krömann, Susanne. Experimenteller Antiinsulinserum-Diabetes bei NMRI-Mäusen unter dem Einfluss von Cyclophosphamid. 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

Schmich, Uwe. Toxizität von Cyclophosphamid, Ifosfamid und deren Metaboliten in renalen epithelialen Zellkulturen. 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Zickert, Daniela. Embryotoxische Auswirkungen von Cyclophosphamid auf die frühe Entwicklung des kultivierten Wachtelembryos. 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lassota, Antje. Zytotoxische Effekte von Cyclophosphamid und seinen Metaboliten in sensitiven und resistenten Zellkultursystemen. 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Hofmann, Petra. In-vivo-Untersuchungen zur Antiklastogenität von Gemüsen gegenüber Benzo(a)pyren und Cyclophosphamid. 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Laber, Peter. Die regionale Perfusion des tumortragenden Rattenbeins mit stabilisiertem, aktiviertem Cyclophosphamid (4-(S-aethanol)-sulfido-Cyclophosphamid): A. Entwicklung eines Perfusionsmodells und Uäberpruäfung der Eignung zur regionalen Tumortherapie an der hinteren Rattenextremitaät ; B. Regionale Perfusionen mit stabilisertem, aktiviertem Cyclophosphamid zur Therapie des Yoshida-Sarkoms an der hinteren Rattenextremitaät. 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

36

Karcher, Kerstin. Über den Einfluss von Hochdosiertem Cyclophosphamid auf die Regulation einer Überempfindlichkeitsreaktion vom verzögerten Typ. 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Frangart-Schmidt, Jutta. Antiklastogene Effekte von Früchten und ausgewählten Inhaltsstoffen gegenüber Benzo(a)pyren und Cyclophosphamid im Mikrokerntest. 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Brandt, Dietrich. Therapeutischer Effekt der Alkylantien Cyclophosphamid und Ifosfamid im Autoimmunmodell der MRL/Ipr-Ipr (Lupus)-Maus. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gutenberg-Universität, Johannes, ed. Einfluss von 6-Merkaptopurin und Cyclophosphamid auf die humorale Immunantwort sowie auf das Differentialblutbild der Ratte. 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hager, Marlin. Hemmeffekte von Obst und Gemüse auf die in vivo Klastogenität von Benzo(a)pyren und Cyclophosphamid. 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

41

Gutenberg-Universität, Johannes, ed. In vivo Effekte von Interleukin-2 und Cyclophosphamid bei Patienten mit fortgeschrittenem malignen Melanom und Nierenzellkarzinom. 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Krausser, Stefan. Der Einfluss von Allopurinol, Cyclophosphamid und 6-Methylmercaptopurinribosid auf die Bildung und Ausscheidung von Purinkörpern beim Hühnerembryo. 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kraatz, Ernst-Günter. Beeinflussung der B- und T-Zellreaktivität bei Mäusen durch eine Kombinationsbehandlung mit Cyclophosphamid oder Adriamycin und Allo-Antigen. 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Rudolf, Jörg. Über die Wirkungsweise von Cyclophosphamid und 6-Merkaptopurin auf das humorale Immunsystem und auf das weisse Blutbild beim Meerschweinchen. 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Brunnengräber, Rita. Zur Wirkung von Ampicillin und Doxycyclin auf das zelluläre und humorale Immunsystem der gesunden und der mit Cyclophosphamid immunsupprimierten Maus. 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Hibbe, Thomas. Immuntherapeutische Effekte von gamma-Interferon, Interleukin-2, Lipopolysacchariden, Cyclophosphamid und Thiamazol im Niedrigdosis-Streptozotocin-Modell und in der NOD-Maus. 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gutenberg-Universität, Johannes, ed. Die in vitro-Chromatresistenz von Lymphozyten nach in vivo-Exposition gegenüber 1,1,1-Trichlorethan. Cyclophosphamid und Azathioprin - ein immuntoxikologisches ELISA-Verfahren. 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Küpper, Silke. Konzentrationen und molares Verhältnis aktiver cytostatischer Metabolite und protektiver Thiole im Plasma von Patienten unter der Therapie mit Ifosfamid / Cyclophosphamid und Mesna. 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

49

Mrakawa, Diana. Induktion von DNA-Strangschäden in venösem Blut von Patientinnen mit Ovarial-Karzinom durch Chemotherapie mit Cyclophosphamid und Carboplatin in Relation zum Therapieerfolg. 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kerkhoff, Guido. Einfluss von Ascorbinsäure, [beta]-Carotin, DL-alpha-Tocopherol, Vitamin A-aldehyd, Vitamin K undRiboflavin auf den durch Cyclophosphamid oder Trp-P-2 induzierten Schwesterchromatidaustausch in menschlichen Lymphozytenkulturen. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!